Cleveland BioLabs wins deal with Russia

Cleveland BioLabs has received $4.6 million in funding from a Russian government agency to help develop a line of anti-infection drugs, the Buffalo-based company said Tuesday.

The contract from the Russian Ministry of Industry and Trade will help the company develop its Xenomycin family of compounds as potential treatments for infections.

The funding, part of the Russian government’s Pharma “2020” drug development initiative, is being funneled through Panacela Labs, a joint venture that Cleveland BioLabs formed last year with a Russian investment company.